COMPANY RESEARCHThe website lists DEL/ASMS ligand discovery, linker design, binary / ternary binding, ubiquitination, HiBiT/NanoBRET, and in vivo PK/PD services.
Profile review: 2026-11-05 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Amounts retain their original currency and units. Consolidated group revenue is not standalone CRO/CDMO service revenue. Year-to-date periods are not standalone quarters.
| Period | Currency / basis | Revenue | Net profit | Operating cash flow | Report |
|---|---|---|---|---|---|
| FY2025 2025-12-31 | CNY PRC Accounting Standards / consolidated | 45,456,165,774.18 | 19,150,582,400.69 Net income attributable to shareholders of the listed company | 17,203,161,622 | Original ↗ |
| 2026Q3 (YTD) 2026-09-30 | CNY PRC Accounting Standards / consolidated | 45,537,430,834.54 | 19,398,304,296.86 Net income attributable to shareholders of the listed company | 17,193,155,723.29 | Original ↗ |
Disease tags match recorded text mentions and require program-level verification.
The website describes a client case for a non-GLP-1 oral cyclic peptide, from library synthesis and lead optimization through GMP preparation. Only service capability is recorded; the unnamed client is neither identified nor guessed.
The website lists DEL/ASMS ligand discovery, linker design, binary / ternary binding, ubiquitination, HiBiT/NanoBRET, and in vivo PK/PD services.
WuXi STA's injectable drug product platform lists mRNA/DNA-LNP and end-to-end LNP services, including lipid discovery, formulation and process development, analysis, and manufacturing.
WuXi STA's drug product services cover oral solids and injectables, integrating API and drug product development, analytical work, and clinical-to-commercial manufacturing.
The STA page explicitly lists salt, cocrystal, and polymorph screening, solid-form quantification, and structural analysis.
The Chemistry crystallization platform discloses polymorph and salt screening, crystallization process development, and crystal habit optimization.
Large-molecule bioanalysis, PK, immunogenicity and biomarkers
Specialist contract research/testing services
The group provides CRDMO services spanning small-molecule research and manufacturing, biology, preclinical testing, and clinical research. Financials are consolidated group figures.
Listed as SSE 603259 / HKEX 02359; original 2025 annual and 2026Q3 (YTD) reports reviewed.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| Oral cyclic peptide CRDMO case study | Not disclosed · Not disclosed | 未披露 | Quantitative human results not confirmed in this review |
| Ligand discovery, synthesis, ternary complexes, proteomics, and DMPK | Program-dependent / not disclosed · Determined by the collaboration program | Platform / services | This record does not claim platform-wide human validation |
| RNA / LNP service capabilities | Project-dependent / not verified · Project-dependent / not verified | Services / platform | This record does not establish human validation of the entire platform |
| Formulation development / contract manufacturing capabilities | Defined by the client project · Defined by the client project | Services / platform | Service pages do not establish human evidence for every project |
| Solid-state R&D capabilities | Determined by the submitted sample and research question · Not applicable; service capability | Services / platform | Not applicable; not a human clinical program |
| End-to-end drug research and manufacturing services | Not applicable (services/platform) · Drug research and manufacturing services for clients | Services / platform | Not applicable: service capabilities are not clinical drug candidates; E4 does not rate service quality. |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
WuXi AppTec reported nine-month 2026 revenue of RMB 45.54 billion, up 38.6% year over year. Revenue from continuing operations rose 46.3%, and continuing-operations backlog reached RMB 76.74 billion, up 36.4%. The company also raised full-year guidance. Total-revenue and continuing-operations growth rates use different reporting scopes and should not be treated as interchangeable.
Johnson & Johnson reported that 58% of patients receiving icotrokinra 200 mg achieved ACR20 at Week 16 in ICONIC-PsA 1, versus 41% with placebo. The oral IL-23 receptor peptide also showed skin responses. The company reported no new safety signals through Week 24; active psoriatic arthritis remains an investigational indication.
Entera reported $265.9 million in cash and cash equivalents at September 30, plus $6.5 million in restricted cash. Its November 6 update targets first site activation for an approximately 900-patient EB613 osteoporosis Phase 3 trial in late 2026. EB613 is an oral PTH(1-34) program, included here as an adjacent oral-peptide delivery development, not a cyclic-peptide candidate.
Johnson & Johnson reported that ICONIC-ASCEND met its Week 16 co-primary endpoints: PASI 90 responses were 55.2% with icotrokinra versus 3.6% with placebo, and IGA 0/1 responses were 70.4% versus 9.5%. At Week 28, the oral peptide met noninferiority criteria versus ustekinumab across multiplicity-controlled key secondary skin-clearance endpoints.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.